MYRIAD GENETICS, INC. Business Acquisition, Pro Forma Revenue
MYRIAD GENETICS, INC. (MYGN) reported Business Acquisition, Pro Forma Revenue of $216.60 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2019-05-08
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2019-03-31 was $216.60M, a 2.52% decline year-over-year.
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2018-12-31 was $216.80M, a 2.03% decline year-over-year.
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2018-09-30 was $212.50M, a 1.43% increase year-over-year.
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2018-03-31 was $222.20M, a 12.85% increase year-over-year.
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for fiscal 2017 was $781.30M, a 3.11% decline from fiscal 2016.
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for fiscal 2016 was $806.40M, a 11.52% increase from fiscal 2015.
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for fiscal 2015 was $723.10M, a 10.45% decline from fiscal 2014.
- MYRIAD GENETICS, INC. business acquisition, pro forma revenue for fiscal 2014 was $807.50M, a 30.28% increase from fiscal 2013.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-03-31 | $216.60M 10-Q · filed 2019-05-08 | $433.40M derived: sum of 2 quarters · filed 2019-05-08 | $645.90M 10-Q · filed 2019-05-08 | |||||
| 2018-12-31 | $216.80M 10-Q · filed 2019-02-06 | $429.30M 10-Q · filed 2019-02-06 | ||||||
| 2018-09-30 | $212.50M 10-Q · filed 2018-11-07 | |||||||
| 2018-03-31 | $222.20M 10-Q · filed 2019-05-08 | $193.50M 10-Q · filed 2018-05-09 | $443.50M derived: sum of 2 quarters · filed 2019-05-08 | $652.40M 10-Q · filed 2019-05-08 | $577.70M 10-Q · filed 2018-05-09 | $852.00M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2017-12-31 | $221.30M 10-Q · filed 2019-02-06 | $194.00M 10-Q · filed 2018-02-07 | $430.20M 10-Q · filed 2019-02-06 | $384.20M 10-Q · filed 2018-02-07 | $629.80M derived: sum of 3 quarters · filed 2019-02-06 | $826.70M derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2017-09-30 | $209.50M 10-Q · filed 2018-11-07 | $190.20M 10-Q · filed 2017-11-08 | $408.50M derived: sum of 2 quarters · filed 2018-11-07 | $605.40M derived: sum of 3 quarters · filed 2018-11-07 | $801.90M derived: sum of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | $199.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | $395.90M derived: sum of 2 quarters · filed 2018-08-24 | $592.40M derived: sum of 3 quarters · filed 2018-08-24 | $781.30M 10-K · filed 2018-08-24 | $782.80M 10-K · filed 2017-08-09 | |||
| 2017-03-31 | $196.90M 10-Q · filed 2018-05-09 | $393.40M derived: sum of 2 quarters · filed 2018-05-09 | $582.30M 10-Q · filed 2018-05-09 | $778.70M derived: sum of 4 quarters · filed 2018-08-24 | ||||
| 2016-12-31 | $196.50M 10-Q · filed 2018-02-07 | $385.40M 10-Q · filed 2018-02-07 | $581.80M derived: sum of 3 quarters · filed 2018-08-24 | $789.20M derived: sum of 4 quarters · filed 2018-08-24 | ||||
| 2016-09-30 | $188.90M 10-Q · filed 2017-11-08 | $385.30M derived: sum of 2 quarters · filed 2018-08-24 | $592.70M derived: sum of 3 quarters · filed 2018-08-24 | $800.80M derived: sum of 4 quarters · filed 2018-08-24 | ||||
| 2016-06-30 | $196.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | $403.80M derived: sum of 2 quarters · filed 2018-08-24 | $611.90M derived: sum of 3 quarters · filed 2018-08-24 | $806.40M 10-K · filed 2018-08-24 | $819.70M 10-K · filed 2017-08-09 | |||
| 2016-03-31 | $207.40M 10-Q · filed 2017-05-03 | $415.50M derived: sum of 2 quarters · filed 2017-05-03 | $610.00M 10-Q · filed 2017-05-03 | $799.88M derived: sum of 4 quarters · filed 2017-05-03 | ||||
| 2015-12-31 | $208.10M 10-Q · filed 2017-02-08 | $402.60M 10-Q · filed 2017-02-08 | $592.48M derived: sum of 3 quarters · filed 2017-02-08 | $772.47M derived: sum of 4 quarters · filed 2017-02-08 | ||||
| 2015-09-30 | $194.50M 10-Q · filed 2016-11-02 | $384.38M derived: sum of 2 quarters · filed 2016-11-02 | $564.37M derived: sum of 3 quarters · filed 2016-11-02 | $748.76M derived: sum of 4 quarters · filed 2016-11-02 | ||||
| 2015-06-30 | $189.88M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-12 | $369.87M derived: sum of 2 quarters · filed 2015-08-12 | $554.26M derived: sum of 3 quarters · filed 2015-08-12 | $723.10M 10-K · filed 2015-08-12 | ||||
| 2015-03-31 | $179.99M 10-Q · filed 2015-05-06 | $364.38M derived: sum of 2 quarters · filed 2015-05-06 | $533.22M 10-Q · filed 2015-05-06 | $721.97M derived: sum of 4 quarters · filed 2015-08-12 | ||||
| 2014-12-31 | $184.39M 10-Q · filed 2015-02-04 | $353.23M 10-Q · filed 2015-02-04 | $541.99M derived: sum of 3 quarters · filed 2015-08-12 | $730.68M derived: sum of 4 quarters · filed 2015-08-12 | ||||
| 2014-09-30 | $168.84M 10-Q · filed 2014-11-05 | $357.59M derived: sum of 2 quarters · filed 2015-08-12 | $546.29M derived: sum of 3 quarters · filed 2015-08-12 | $771.99M derived: sum of 4 quarters · filed 2015-08-12 | ||||
| 2014-06-30 | $188.76M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-12 | $377.45M derived: sum of 2 quarters · filed 2015-08-12 | $603.15M derived: sum of 3 quarters · filed 2015-08-12 | $807.50M 10-K · filed 2015-08-12 | $807.51M 10-K · filed 2014-08-13 | |||
| 2014-03-31 | $188.69M 10-Q · filed 2015-05-06 | $414.39M derived: sum of 2 quarters · filed 2015-05-06 | $618.74M 10-Q · filed 2015-05-06 | $794.76M derived: sum of 4 quarters · filed 2015-05-06 | ||||
| 2013-12-31 | $225.70M 10-Q · filed 2015-02-04 | $430.05M 10-Q · filed 2015-02-04 | $606.07M derived: sum of 3 quarters · filed 2015-02-04 | $764.42M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-09-30 | $204.35M 10-Q · filed 2014-11-05 | $380.37M derived: sum of 2 quarters · filed 2014-11-05 | $538.72M derived: sum of 3 quarters · filed 2014-11-05 | |||||
| 2013-06-30 | $176.01M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-13 | $334.37M derived: sum of 2 quarters · filed 2014-08-13 | $619.84M 10-K · filed 2014-08-13 | |||||
| 2013-03-31 | $158.36M 10-Q · filed 2014-05-07 | $443.82M 10-Q · filed 2014-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |